Prostate cancer screening

Last updated
Prostate cancer screening
PurposeDetect prostate cancer (when no symptoms are present)

Prostate cancer screening is the screening process used to detect undiagnosed prostate cancer in men without signs or symptoms. [1] [2] When abnormal prostate tissue or cancer is found early, it may be easier to treat and cure, but it is unclear if early detection reduces mortality rates. [2]

Contents

Screening precedes a diagnosis and subsequent treatment. The digital rectal examination (DRE) is one screening tool, during which the prostate is manually assessed through the wall of the rectum. The second screening tool is the measurement of prostate-specific antigen (PSA) in the blood. The evidence remains insufficient to determine whether screening with PSA or DRE reduces mortality from prostate cancer. [1] A 2013 Cochrane review concluded PSA screening results in "no statistically significant difference in prostate cancer-specific mortality...". [3] The American studies were determined to have a high bias. European studies included in this review were of low bias and one reported "a significant reduction in prostate cancer-specific mortality." PSA screening with DRE was not assessed in this review. DRE was not assessed separately. [3]

Most recent guidelines have recommended that the decision whether or not to screen should be based on shared decision-making, [4] so that men are informed of the risks and benefits of screening. [5] [6] In 2012, the American Society of Clinical Oncology recommends screening be discouraged for those who are expected to live less than ten years, while for those with a longer life expectancy a decision should be made by the person in question. In general, they conclude that based on recent research, "it is uncertain whether the benefits associated with PSA testing for prostate cancer screening are worth the harms associated with screening and subsequent unnecessary treatment." [7]

Prostate biopsies are used to diagnose prostate cancer but are not done on asymptomatic men and therefore are not used for screening. [8] [9] Infection after prostate biopsy occurs in about 1%, while death occurs as a result of biopsy in 0.2%. [10] [11] Prostate biopsy guided by magnetic resonance imaging has improved the diagnostic accuracy of the procedure. [12] [13]

Prostate-specific antigen

Prostate-specific antigen PSA KLK3 PDB 2ZCK.png
Prostate-specific antigen

Prostate-specific antigen (PSA) is secreted by the epithelial cells of the prostate gland and can be detected in a sample of blood. [14] PSA is present in small quantities in the serum of men with healthy prostates, but is often elevated in the presence of prostate cancer or other prostate disorders. [15] PSA is not a unique indicator of prostate cancer, but may also detect prostatitis or benign prostatic hyperplasia. [16]

A 2018 United States Preventive Services Task Force (USPSTF) draft adjusted the prior opposition to PSA screening. [17] It suggests shared decision-making regarding screening in healthy males 55 to 69 years of age. [17] The final recommendation for that age group states screening should only be done in those who wish it. [18] In those 70 and over, screening remains not recommended. [18]

Screening with PSA has been associated with a number of harms including over-diagnosis, increased prostate biopsy with associated harms, increased anxiety, and unneeded treatment. [19] The evidence surrounding prostate cancer screening indicates that it may cause little to no difference in mortality. [3]

On the other hand, up to 25% of men diagnosed in their 70s or even 80s die of prostate cancer, if they have high-grade (i.e., aggressive) prostate cancer. [20] Conversely, some argue against PSA testing for men who are too young, because too many men would have to be screened to find one cancer, and too many men would have treatment for cancer that would not progress. Low-risk prostate cancer does not always require immediate treatment, but may be amenable to active surveillance. [21] A PSA test cannot 'prove' the existence of prostate cancer by itself; varying levels of the antigen can be due to other causes. [22]

Digital rectal examination

During a digital rectal examination (DRE), a healthcare provider slides a gloved finger into the rectum and presses on the prostate, to check its size and to detect any lumps on the accessible side. If the examination suggests anomalies, a PSA test is performed. If an elevated PSA level is found, a follow-up test is then performed. [2]

A 2018 review recommended against primary care screening for prostate cancer with DRE due to the lack of evidence of the effectiveness of the practice. [23]

The USPSTF recommends against digital rectal examination as a screening tool due to lack of evidence of benefits. [24] Although DRE has long been used to diagnose prostate cancer, no controlled studies have shown a reduction in the morbidity or mortality of prostate cancer when detected by DRE at any age. [25] [26]

The American Urological Association in 2018 stated that for men aged 55 to 69, they could find no evidence to support the continued use of DRE as a first-line screening test; however, in men referred for an elevated PSA, DRE may be a useful secondary test. [27]

A study by Krilaviciute et al. (2023) [28] examined the effectiveness of the DRE as a standalone screening test for prostate cancer in >46,000 young men in Germany (age 45). It was found that DRE has a much lower detection rate for prostate cancer compared to PSA screening. Therefore, the authors recommend not to use DRE as a screening test for prostate cancer in young men, as it does not provide an improvement in detection compared to PSA screening.

Follow-up tests

Biopsy

Prostate biopsies are considered the gold standard in detecting prostate cancer. [8] [9] Infection is a possible risk. [10] MRI guided techniques have improved the diagnostic accuracy of the procedure. [12] [13] Biopsies can be done through the rectum or penis. [29] The biopsy technique includes factors such as needle angle and prostate mapping method. [30] Patients with localized cancer and perineural invasion may benefit more from immediate treatment rather than adopting a watchful waiting approach. [30]

Ultrasound

Transrectal ultrasonography (TRUS) has the advantage of being fast and minimally invasive, and better than MRI for the evaluation of superficial tumor. [2] It also gives details about the layers of the rectal wall, accurate and useful for staging primary rectal cancer. While MRI is better in visualization of locally advanced and stenosing cancers, for staging perirectal lymph nodes, both TRUS and MRI are capable. TRUS has a small field of view, but 3D TRUS can improve the diagnosis of anorectal diseases. [31]

Magnetic Resonance Imaging

MRI is used when screening suggests a malignancy. [32] This model potentially minimizes unnecessary prostate biopsies while maximizing biopsy yield. [33] [ dubious – discuss ][ citation needed ] Despite concerns about the cost of MRI scans, compared to the long-term cost burden of the PSA/TRUS biopsy-based standard of care, the imaging model has been found to be cost-effective.[ dubious – discuss ][ citation needed ] MRI imaging can be used for patients who have had a previous negative biopsy but their PSA continues to increase. [34] Consensus has not been determined as to which of the MRI-targeted biopsy techniques is more useful. [35] In a study involving 400 men aged 50 – 69, MRI screening identified more men with prostate cancer than PSA tests or ultrasound and did not increase the number of men who needed a biopsy. [36] [37] A large-scale trial of MRI screening, TRANSFORM, began in the UK in spring 2024. [38]

Other imaging

68Ga-PSMA PET/CT imaging has become, in a relatively short period of time, the gold standard for restaging recurrent prostate cancer in clinical centers in which this imaging modality is available. [39] It is likely to become the standard imaging modality in the staging of intermediate-to-high risk primary prostate cancer. [39] The potential to guide therapy, and to facilitate more accurate prostatic biopsy is being explored. [39] In the theranostic paradigm, 68Ga-PSMA PET/CT imaging is critical for detecting prostate specific membrane antigen-avid disease which may then respond to targeted 177Lu-PSMA or 225Ac-PSMA therapies. [39] For local recurrence, 68Ga-PSMA PET/MR or PET/CT in combination with mpMR is most appropriate. [40] PSMA PET/CT may be potentially helpful for locating the cancer when combined with multiparametric MRI (mpMRI) for primary prostate care. [41] Prostate multiparametric MR imaging (mpMRI) is helpful in evaluating recurrence of primary prostate cancer following treatment. [42]

Other

A number of biomarkers for prostate cancer exist. [43] [44] These include the following blood, urine and tissue based tests:

Researchers at the Korea Institute of Science and Technology (KIST) developed a urinary multi marker sensor with the ability to measure trace amounts of biomarkers from naturally voided urine. [48] The correlation of clinical state with the sensing signals form urinary multi markers was analyzed by two machine learning algorithms, random forest and neural network. Both algorithms provided a monotonic increase in screening performance as the number of biomarkers was increased. With the best combination of biomarkers, the algorithms were able to screen prostate cancer patients with more than 99% accuracy. [48]

Guidelines

Controversy

Screening for prostate cancer continues to generate debate among clinicians and broader lay audiences. [53] Publications authored by governmental, non-governmental and medical organizations continue the debate and publish recommendations for screening. [3] One in six men will be diagnosed with prostate cancer during their lifetime but screening may result in the overdiagnosis and overtreatment of prostate cancer. [54] [55] Though the death rates from prostate cancer continue to decline, 238,590 men were diagnosed with prostate cancer in the United States in 2013 while 29,720 died as a result. Death rates from prostate cancer have declined at a steady rate since 1992. Cancers of the prostate, lung and bronchus, and colorectum accounted for about 50% of all newly diagnosed cancers in American men in 2013, with prostate cancer constituting 28% of cases. Screening for prostate cancer varies by state and indicates differences in the use of screening for prostate cancer as well as variations between locales. Out of all cases of prostate cancer, African American men have an incidence of 62%. African American men are less likely to receive standard therapy for prostate cancer. This discrepancy may indicate that if they were to receive higher quality cancer treatment their survival rates would be similar to whites. [54]

Prostate cancer is also extremely heterogeneous: most prostate cancers are indolent and would never progress to a clinically meaningful stage if left undiagnosed and untreated during a man's lifetime. On the other hand, a subset are potentially lethal, and screening can identify some of these within a window of opportunity for cure. [56] Thus, PSA screening is advocated by some as a means of detecting high-risk, potentially lethal prostate cancer, with the understanding that lower-risk disease, if discovered, often does not need treatment and may be amenable to active surveillance. [21] [57]

Screening for prostate cancer is controversial because of cost and uncertain long-term benefits to patients. [58] Horan echos that sentiment in his book. [59] Private medical institutes, such as the Mayo Clinic, likewise acknowledge that "organizations vary in their recommendations about who should – and who shouldn't – get a PSA screening test. They conclude: "Ultimately, whether you should have a PSA test is something you'll have to decide after discussing it with your doctor, considering your risk factors and weighing your personal preferences." [60]

A 2009 study in Europe resulted in only a small decline in death rates and concluded that 48 men would need to be treated to save one life. But of the 47 men who were treated, most would be unable to ever again function sexually and would require more frequent trips to the bathroom. [59] [ page needed ] Aggressive marketing of screening tests by drug companies has also generated controversy as has the advocacy of testing by the American Urological Association. [59]

One commentator observed in 2011: “[I]t is prudent only to use a single PSA determination as a baseline, with biopsy and cancer treatment reserved for those with significant PSA changes over time, or for those with clinical manifestations mandating immediate therapy..... absolute levels of PSA are rarely meaningful; it is the relative change in PSA levels over time that provides insight, but not definitive proof of a cancerous condition necessitating therapy.“ [61]

Men report low levels of distress surrounding PSA screening. [62] Men who present for PSA or have PSA levels at baseline scored low on cancer distress on numerous scales. [62]

History

Global comparisons of prostate cancer screening Prostate cancer global epidemiology.png
Global comparisons of prostate cancer screening

Screening of PSA began in the 1990s. In the European Randomized Study of Screening for Prostate Cancer (ERSPC) initiated in the early 1990s, the researchers concluded that PSA-based screening did reduce the rate of death from prostate cancer but created a high risk of overdiagnosis, i.e., 1410 men would need to be screened and 48 additional cases of prostate cancer would need to be treated to prevent just one death from prostate cancer within 9 years. [63]

A study published in the European Journal of Cancer (October 2009) documented that prostate cancer screening reduced prostate cancer mortality by 37 percent. By utilizing a control group of men from Northern Ireland, where PSA screening is infrequent, the research showed this substantial reduction in prostate cancer deaths when compared to men who were PSA tested as part of the ERSPC study. [64]

A study published in the New England Journal of Medicine in 2009 found that over a 7 to 10-year period, "screening did not reduce the death rate in men 55 and over." [59] Former screening proponents, including some from Stanford University, have come out against routine testing. In February 2010, the American Cancer Society urged "more caution in using the test." And the American College of Preventive Medicine concluded that "there was insufficient evidence to recommend routine screening." [59]

A further study, the NHS Comparison Arm for ProtecT (CAP), as part of the Prostate testing for cancer and Treatment (ProtecT) study, randomized GP practices with 460,000 men aged 50–69 at centers in 9 cities in Britain from 2001–2005 to usual care or prostate cancer screening with PSA (biopsy if PSA ≥ 3). [65] The "Comparison Arm" has yet to report as of early 2018. [66]

See also

Related Research Articles

<span class="mw-page-title-main">Prostate</span> Gland of the male reproductive system in most mammals

The prostate is both an accessory gland of the male reproductive system and a muscle-driven mechanical switch between urination and ejaculation. It is found in all male mammals. It differs between species anatomically, chemically, and physiologically. Anatomically, the prostate is found below the bladder, with the urethra passing through it. It is described in gross anatomy as consisting of lobes and in microanatomy by zone. It is surrounded by an elastic, fibromuscular capsule and contains glandular tissue, as well as connective tissue.

<span class="mw-page-title-main">Prostate cancer</span> Male reproductive organ cancer

Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system below the bladder. Early prostate cancer causes no symptoms. Abnormal growth of prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA) levels. Those with high levels of PSA in their blood are at increased risk for developing prostate cancer. Diagnosis requires a biopsy of the prostate. If cancer is present, the pathologist assigns a Gleason score, and a higher score represents a more dangerous tumor. Medical imaging is performed to look for cancer that has spread outside the prostate. Based on the Gleason score, PSA levels, and imaging results, a cancer case is assigned a stage 1 to 4. Higher stage signifies a more advanced, more dangerous disease.

<span class="mw-page-title-main">Benign prostatic hyperplasia</span> Noncancerous increase in size of the prostate gland

Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate gland. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems.

<span class="mw-page-title-main">Prostate-specific antigen</span> Mammalian protein found in humans

Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), P-30 antigen, is a glycoprotein enzyme encoded in humans by the KLK3 gene. PSA is a member of the kallikrein-related peptidase family and is secreted by the epithelial cells of the prostate gland in men and the paraurethral glands in women.

<span class="mw-page-title-main">Rectal examination</span> Medical assessment or diagnostic procedure

Digital rectal examination (DRE), also known as a prostate exam, is an internal examination of the rectum performed by a healthcare provider.

<span class="mw-page-title-main">Prostate biopsy</span>

Prostate biopsy is a procedure in which small hollow needle-core samples are removed from a man's prostate gland to be examined for the presence of prostate cancer. It is typically performed when the result from a PSA blood test is high. It may also be considered advisable after a digital rectal exam (DRE) finds possible abnormality. PSA screening is controversial as PSA may become elevated due to non-cancerous conditions such as benign prostatic hyperplasia (BPH), by infection, or by manipulation of the prostate during surgery or catheterization. Additionally many prostate cancers detected by screening develop so slowly that they would not cause problems during a man's lifetime, making the complications due to treatment unnecessary.

A gallium scan is a type of nuclear medicine test that uses either a gallium-67 (67Ga) or gallium-68 (68Ga) radiopharmaceutical to obtain images of a specific type of tissue, or disease state of tissue. Gallium salts like gallium citrate and gallium nitrate may be used. The form of salt is not important, since it is the freely dissolved gallium ion Ga3+ which is active. Both 67Ga and 68Ga salts have similar uptake mechanisms. Gallium can also be used in other forms, for example 68Ga-PSMA is used for cancer imaging. The gamma emission of gallium-67 is imaged by a gamma camera, while the positron emission of gallium-68 is imaged by positron emission tomography (PET).

Early prostate cancer antigen-2 (EPCA-2) is a protein of which blood levels are elevated in prostate cancer. It appears to provide more accuracy in identifying early prostate cancer than the standard prostate cancer marker, PSA.

<span class="mw-page-title-main">Glutamate carboxypeptidase II</span> Enzyme

Glutamate carboxypeptidase II (GCPII), also known as N-acetyl-L-aspartyl-L-glutamate peptidase I, NAAG peptidase, or prostate-specific membrane antigen (PSMA) is an enzyme that in humans is encoded by the FOLH1 gene. Human GCPII contains 750 amino acids and weighs approximately 84 kDa.

Lower urinary tract symptoms (LUTS) refer to a group of clinical symptoms involving the bladder, urinary sphincter, urethra and, in men, the prostate. The term is more commonly applied to men – over 40% of older men are affected – but lower urinary tract symptoms also affect women. The condition is also termed prostatism in men, but LUTS is preferred.

<span class="mw-page-title-main">PCA3</span> Non-coding RNA in the species Homo sapiens

Prostate cancer antigen 3 is a gene that expresses a non-coding RNA. PCA3 is only expressed in human prostate tissue, and the gene is highly overexpressed in prostate cancer. Because of its restricted expression profile, the PCA3 RNA is useful as a tumor marker.

Douglas S. Scherr, M.D. is an American surgeon and specialist in Urologic Oncology. He is currently the Clinical Director of Urologic Oncology at Weill Cornell Medicine. He also holds an appointment at the Rockefeller University as a Visiting Associate Physician. Scherr was the first physician at Cornell to perform a robotic prostatectomy as well as a robotic cystectomy.

<span class="mw-page-title-main">Cancer screening</span> Method to detect cancer

The objective of cancer screening is to detect cancer before symptoms appear, involving various methods such as blood tests, urine tests, DNA tests, and medical imaging. The purpose of screening is early cancer detection, to make the cancer easier to treat and extending life expectancy. In 2019, cancer was the second leading cause of death globally; more recent data is pending due to the COVID-19 pandemic.

Treatment for prostate cancer may involve active surveillance, surgery, radiation therapy – including brachytherapy and external-beam radiation therapy, proton therapy, high-intensity focused ultrasound (HIFU), cryosurgery, hormonal therapy, chemotherapy, or some combination. Treatments also extend to survivorship based interventions. These interventions are focused on five domains including: physical symptoms, psychological symptoms, surveillance, health promotion and care coordination. However, a published review has found only high levels of evidence for interventions that target physical and psychological symptom management and health promotion, with no reviews of interventions for either care coordination or surveillance. The favored treatment option depends on the stage of the disease, the Gleason score, and the PSA level. Other important factors include the man's age, his general health, and his feelings about potential treatments and their possible side-effects. Because all treatments can have significant side-effects, such as erectile dysfunction and urinary incontinence, treatment discussions often focus on balancing the goals of therapy with the risks of lifestyle alterations.

<span class="mw-page-title-main">Active surveillance of prostate cancer</span>

Active surveillance is a management option for localized prostate cancer that can be offered to appropriate patients who would also be candidates for aggressive local therapies, with the intent to intervene if the disease progresses. Active surveillance should not be confused with watchful waiting, another observational strategy for men that would not be candidates for curative therapy because of a limited life expectancy. Active surveillance offers men with a prostate cancer that is thought to have a low risk of causing harm in the absence of treatment, a chance to delay or avoid aggressive treatment and its associated side effects. While prostate cancer is the most common non-cutaneous cancer and second leading cause of cancer-related death in American men, it is conservatively estimated that approximately 100,000 men per year in the United States who would be eligible for conservative treatment through active surveillance, undergo unnecessary treatments. The management of localized prostate cancer is controversial and men with localized disease diagnosed today often undergo treatments with significant side effects that will not improve overall health outcomes. The 2011 NIH State-of-the-Science Conference Statement on the "Role of active surveillance in the management of men with localized prostate cancer" pointed out the many unanswered questions about observational strategies for prostate cancer that require further research and clarification. These included:

Andrew Julian Vickers is a biostatistician and attending research methodologist at Memorial Sloan Kettering Cancer Center. Since 2013, he has also been professor of public health at Weill Cornell Medical College. He is the statistical editor for the peer-reviewed journal European Urology.

PI-RADS is an acronym for Prostate Imaging Reporting and Data System, defining standards of high-quality clinical service for multi-parametric magnetic resonance imaging (mpMRI), including image creation and reporting.

A PSMA scan is a nuclear medicine imaging technique used in the diagnosis and staging of prostate cancer. It is carried out by injection of a radiopharmaceutical with a positron or gamma emitting radionuclide and a prostate-specific membrane antigen (PSMA) targeting ligand. After injection, imaging of positron emitters such as gallium-68 (68Ga), copper-64 (64Cu), and fluorine-18 (18F) is carried out with a positron emission tomography (PET) scanner. For gamma emitters such as technetium-99m (99mTc) and indium-111 (111In) single-photon emission computed tomography (SPECT) imaging is performed with a gamma camera.

Declan G. Murphy, FRACS, FRCS, is a urologist, director of the unit for genitourinary oncology and robotic surgery at the Peter MacCallum Cancer Centre in Melbourne, Australia, professor at the Sir Peter MacCallum Department of Oncology at the University of Melbourne, and associate editor of the British Journal of Urology International. In 2010 he introduced robotic surgery for urology to the public sector health services in Victoria, Australia.

Gallium (<sup>68</sup>Ga) gozetotide Radiopharmaceutical medication

Gallium (68Ga) gozetotide or Gallium (68Ga) PSMA-11 sold under the brand name Illuccix among others, is a radiopharmaceutical made of 68Ga conjugated to prostate-specific membrane antigen (PSMA) targeting ligand, Glu-Urea-Lys(Ahx)-HBED-CC, used for imaging prostate cancer by positron emission tomography (PET). The PSMA targeting ligand specifically directs the radiolabeled imaging agent towards the prostate cancerous lesions in men.

References

  1. 1 2 PDQ Screening and Prevention Editorial Board (2018). "Prostate Cancer Screening (PDQ®): Health Professional Version". PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US). PMID   26389383.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  2. 1 2 3 4 "Prostate Cancer Screening-Professional Version". National Cancer Institute. 1980-01-01. Retrieved 2018-02-28.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  3. 1 2 3 4 Ilic D, Neuberger MM, Djulbegovic M, Dahm P (January 2013). "Screening for prostate cancer". The Cochrane Database of Systematic Reviews. 2013 (1): CD004720. doi:10.1002/14651858.cd004720.pub3. PMC   8406915 . PMID   23440794.
  4. ↑ "Prostate Cancer Guidelines". Emedicine. 2017. Retrieved 18 February 2018.
  5. ↑ Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. (January 2013). "Prostate specific antigen best practice statement: 2009 update". The Journal of Urology. 189 (1 Suppl): S2–S11. doi:10.1016/j.juro.2012.11.014. PMID   23234625.
  6. ↑ Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, et al. (Mar–Apr 2010). "American Cancer Society guideline for the early detection of prostate cancer: update 2010". CA: A Cancer Journal for Clinicians. 60 (2): 70–98. doi: 10.3322/caac.20066 . PMID   20200110. S2CID   21548482.
  7. ↑ Basch E, Oliver TK, Vickers A, Thompson I, Kantoff P, Parnes H, et al. (August 2012). "Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion". Journal of Clinical Oncology. 30 (24): 3020–5. doi:10.1200/JCO.2012.43.3441. PMC   3776923 . PMID   22802323.
  8. 1 2 Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, et al. (March 2017). "Complications After Systematic, Random, and Image-guided Prostate Biopsy". European Urology. 71 (3): 353–365. doi:10.1016/j.eururo.2016.08.004. hdl: 11585/559951 . PMID   27543165.
  9. 1 2 Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. (December 2013). "Systematic review of complications of prostate biopsy". European Urology. 64 (6): 876–92. doi: 10.1016/j.eururo.2013.05.049 . PMID   23787356.
  10. 1 2 Bennett HY, Roberts MJ, Doi SA, Gardiner RA (June 2016). "The global burden of major infectious complications following prostate biopsy". Epidemiology and Infection. 144 (8): 1784–91. doi:10.1017/S0950268815002885. PMC   9150640 . PMID   26645476. S2CID   82280.
  11. 1 2 3 Bell N, Connor Gorber S, Shane A, Joffres M, Singh H, Dickinson J, et al. (Canadian Task Force on Preventive Health Care) (4 November 2014). "Recommendations on screening for prostate cancer with the prostate-specific antigen test". Canadian Medical Association Journal. 186 (16): 1225–34. doi:10.1503/cmaj.140703. PMC   4216256 . PMID   25349003.
  12. 1 2 Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG (September 2015). "Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis". European Urology. 68 (3): 438–50. doi:10.1016/j.eururo.2014.11.037. PMID   25480312.
  13. 1 2 Wegelin O, van Melick HH, Hooft L, Bosch JL, Reitsma HB, Barentsz JO, et al. (April 2017). "Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique?". European Urology. 71 (4): 517–531. doi:10.1016/j.eururo.2016.07.041. PMID   27568655.
  14. ↑ Hellstrom WJG, ed. (1999). "Chapter 8: What is the prostate and what is its function?". American Society of Andrology Handbook. San Francisco: American Society of Andrology. ISBN   978-1-891276-02-6. Archived from the original on 2010-01-12. Retrieved 2018-02-28.
  15. ↑ Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. (May 1994). "Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men". The Journal of Urology. 151 (5): 1283–90. doi:10.1016/S0022-5347(17)35233-3. PMID   7512659.
  16. ↑ Velonas VM, Woo HH, dos Remedios CG, Assinder SJ (May 2013). "Current status of biomarkers for prostate cancer". International Journal of Molecular Sciences. 14 (6): 11034–60. doi: 10.3390/ijms140611034 . PMC   3709717 . PMID   23708103.
  17. 1 2 Catalona WJ (March 2018). "Prostate Cancer Screening". The Medical Clinics of North America. 102 (2): 199–214. doi:10.1016/j.mcna.2017.11.001. PMC   5935113 . PMID   29406053.
  18. 1 2 Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, et al. (8 May 2018). "Screening for Prostate Cancer". JAMA. 319 (18): 1901–1913. doi: 10.1001/jama.2018.3710 . PMID   29801017. Clinicians should not screen men who do not express a preference for screening.
  19. ↑ Stewart RW, Lizama S, Peairs K, Sateia HF, Choi Y (February 2017). "Screening for prostate cancer". Seminars in Oncology. 44 (1): 47–56. doi:10.1053/j.seminoncol.2017.02.001. PMID   28395763.
  20. ↑ Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. (September 2009). "Outcomes of localized prostate cancer following conservative management". JAMA. 302 (11): 1202–9. doi:10.1001/jama.2009.1348. PMC   2822438 . PMID   19755699.
  21. 1 2 Cooperberg MR, Carroll PR, Klotz L (September 2011). "Active surveillance for prostate cancer: progress and promise". Journal of Clinical Oncology. 29 (27): 3669–76. doi: 10.1200/JCO.2011.34.9738 . PMID   21825257. S2CID   24885033.
  22. 1 2 "Prostate cancer - PSA testing - NHS Choices". NHS Choices. 3 January 2015.
  23. ↑ Naji L, Randhawa H, Sohani Z, Dennis B, Lautenbach D, Kavanagh O, et al. (12 March 2018). "Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis". The Annals of Family Medicine. 16 (2): 149–154. doi:10.1370/afm.2205. PMC   5847354 . PMID   29531107.
  24. ↑ Tseng CW, Siu AL, Simon MA, Silverstein M, Mangione CM, Landefeld CS, et al. (2018-05-08). "Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement". JAMA. 319 (18): 1901–1913. doi: 10.1001/jama.2018.3710 . ISSN   0098-7484. PMID   29801017.
  25. ↑ "UpToDate". www.uptodate.com. Retrieved 2019-02-07.
  26. ↑ Campbell's Urology 8th Edition. 2002. pp. Epstein JI. Pathology of prostatic neoplasia.
  27. 1 2 "Prostate Cancer: Early Detection Guideline - American Urological Association". www.auanet.org. Archived from the original on 2017-02-06. Retrieved 2019-10-10.
  28. ↑ Krilaviciute A, Becker N, Lakes J, Radtke JP, Kuczyk M, Peters I, et al. (2023). "Digital Rectal Examination is Not a Useful Screening Test for Prostate Cancer". European Urology Oncology. 6 (6): S2588–9311(23)00203-1. doi:10.1016/j.euo.2023.09.008. PMID   37806841. S2CID   263773728.
  29. ↑ "Prostate Biopsy". www.hopkinsmedicine.org. 2023-12-04. Retrieved 2024-03-15.
  30. 1 2 Harnden P, Shelley MD, Clements H, Coles B, Tyndale-Biscoe RS, Naylor B, et al. (January 2007). "The prognostic significance of perineural invasion in prostatic cancer biopsies: A systematic review". Cancer. 109 (1): 13–24. doi: 10.1002/cncr.22388 . ISSN   0008-543X.
  31. ↑ Kim MJ (January 2015). "Transrectal ultrasonography of anorectal diseases: advantages and disadvantages". Ultrasonography. 34 (1): 19–31. doi:10.14366/usg.14051. PMC   4282231 . PMID   25492891.
  32. 1 2 3 Sarkar S, Das S (2016-03-02). "A Review of Imaging Methods for Prostate Cancer Detection". Biomedical Engineering and Computational Biology. 7 (Suppl 1): 1–15. doi:10.4137/BECB.S34255. PMC   4777886 . PMID   26966397.
  33. ↑ Bjurlin MA, Taneja SS (1 May 2015). "Standards for prostate biopsy". Current Opinion in Urology. 24 (2). Curr Opin Urol: 155–161. doi:10.1097/MOU.0000000000000031. PMC   4142196 . PMID   24451092.
  34. ↑ Turkbey B, Choyke PL (2018). "Future Perspectives and Challenges of Prostate MR Imaging". Radiologic Clinics of North America. 56 (2): 327–337. doi:10.1016/j.rcl.2017.10.013. ISSN   0033-8389. PMC   5808592 . PMID   29420986.
  35. ↑ Giganti F, Moore CM (2017). "A critical comparison of techniques for MRI-targeted biopsy of the prostate". Translational Andrology and Urology. 6 (3): 432–443. doi: 10.21037/tau.2017.03.77 . ISSN   2223-4683. PMC   5503959 . PMID   28725585.
  36. ↑ Eldred-Evans D, Burak P, Connor MJ, Day E, Evans M, Fiorentino F, et al. (2021-03-01). "Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study". JAMA Oncology. 7 (3): 395–402. doi:10.1001/jamaoncol.2020.7456. ISSN   2374-2437. PMC   7879388 . PMID   33570542.
  37. ↑ "MRI screening for prostate cancer shows promise". NIHRE Evidence. 13 March 2024. doi:10.3310/nihrevidence_62211.
  38. ↑ "TRANSFORM trial". Prostate Cancer UK. Retrieved 2024-04-12.
  39. 1 2 3 4 Lenzo NP, Meyrick D, Turner JH (February 2018). "Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer". Diagnostics. 8 (1): 16. doi: 10.3390/diagnostics8010016 . PMC   5871999 . PMID   29439481. Creative Commons by small.svg  This article incorporates text by Nat P. Lenzo, Danielle Meyrick, and J. Harvey Turner available under the CC BY 4.0 license.
  40. ↑ Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C (March 2018). "Current status of theranostics in prostate cancer". European Journal of Nuclear Medicine and Molecular Imaging. 45 (3): 471–495. doi:10.1007/s00259-017-3882-2. PMC   5787224 . PMID   29282518. Creative Commons by small.svg  This article incorporates text by Irene Virgolini, Clemens Decristoforo, Alexander Haug, Stefano Fanti, and Christian Uprimny available under the CC BY 4.0 license.
  41. ↑ Bouchelouche K, Choyke PL (2018). "Advances in prostate-specific membrane antigen PET of prostate cancer". Current Opinion in Oncology. 30 (3): 189–196. doi:10.1097/CCO.0000000000000439. ISSN   1040-8746. PMC   6003670 . PMID   29465429.
  42. ↑ Gaur S, Turkbey B (2018). "Prostate MR Imaging for Posttreatment Evaluation and Recurrence". Radiologic Clinics of North America. 56 (2): 263–275. doi:10.1016/j.rcl.2017.10.008. ISSN   0033-8389. PMC   5844499 . PMID   29420981.
  43. 1 2 Kretschmer A, Tilki D (2017). "Biomarkers in prostate cancer – Current clinical utility and future perspectives". Critical Reviews in Oncology/Hematology. 120: 180–193. doi:10.1016/j.critrevonc.2017.11.007. ISSN   1040-8428. PMID   29198331.
  44. 1 2 Eskra JN, Rabizadeh D, Pavlovich CP, Catalona WJ, Luo J (September 2019). "Approaches to urinary detection of prostate cancer". Prostate Cancer and Prostatic Diseases. 22 (3): 362–381. doi:10.1038/s41391-019-0127-4. ISSN   1365-7852. PMC   6640078 . PMID   30655600.
  45. ↑ Pchejetski D, Hunter E, Dezfouli M, Salter M, Powell R, Green J, Naithani T, Koutsothanasi C, Alshaker H, Jaipuria J, Connor MJ, Eldred-Evans D, Fiorentino F, Ahmed H, Akoulitchev A, Winkler M. "Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection." Cancers (Basel). 2023 Jan 29;15(3):821. doi: 10.3390/cancers15030821. PMID: 36765779; PMCID: PMC9913359.
  46. 1 2 3 4 5 6 7 Rendon RA, Mason RJ, Marzouk K, Finelli A, Saad F, So A, et al. (October 2017). "Canadian Urological Association recommendations on prostate cancer screening and early diagnosis". Canadian Urological Association Journal. 11 (10): 298–309. doi:10.5489/cuaj.4888. PMC   5659858 . PMID   29381452.
  47. ↑ Progensa PCA3 Assay [package insert]. 502083-IFU-PI, Rev. 001. San Diego, CA: Hologic, Inc.; 2015.
  48. 1 2 Kim H, Park S, Jeong IG, Song SH, Jeong Y, Kim CS, et al. (9 December 2020). "Noninvasive Precision Screening of Prostate Cancer by Urinary Multimarker Sensor and Artificial Intelligence Analysis". ACS Nano. 15 (3): 4054–4065. doi:10.1021/acsnano.0c06946. PMID   33296173. S2CID   228089390.
  49. ↑ "Final Update Summary: Prostate Cancer: Screening - US Preventive Services Task Force". www.uspreventiveservicestaskforce.org. Retrieved 2 March 2018.
  50. 1 2 "Home Page - USPSTF Draft Prostate Screening Recommendations". USPSTF Draft Prostate Screening Recommendations. Archived from the original on 2 March 2018. Retrieved 2 March 2018.
  51. ↑ Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, et al. (2010). "American Cancer Society guideline for the early detection of prostate cancer: update 2010". CA: A Cancer Journal for Clinicians. 60 (2): 70–98. doi: 10.3322/caac.20066 . PMID   20200110. S2CID   21548482.
  52. 1 2 Fleshner K, Carlsson SV, Roobol MJ (2016). "The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA". Nature Reviews Urology. 14 (1): 26–37. doi:10.1038/nrurol.2016.251. ISSN   1759-4812. PMC   5341610 . PMID   27995937.
  53. ↑ Sadi MV (2017). "PSA screening for prostate cancer". Revista da Associação Médica Brasileira. 63 (8): 722–725. doi: 10.1590/1806-9282.63.08.722 . ISSN   0104-4230. PMID   28977112.
  54. 1 2 Siegel R, Naishadham D, Jemal A (January 2013). "Cancer statistics, 2013". CA: A Cancer Journal for Clinicians. 63 (1): 11–30. doi: 10.3322/caac.21166 . PMID   23335087. S2CID   24926725.
  55. ↑ Ashley VA, Joseph MB, Kamlesh KY, Shalini SY, Ashutosh KT, Joseph R (2017). "The Use of Biomarkers in Prostate Cancer Screening and Treatment". Reviews in Urology. 19 (4): 221–234. doi:10.3909/riu0772 (inactive 31 January 2024). PMC   5811879 . PMID   29472826.{{cite journal}}: CS1 maint: DOI inactive as of January 2024 (link)
  56. ↑ Esserman L, Shieh Y, Thompson I (October 2009). "Rethinking screening for breast cancer and prostate cancer". JAMA. 302 (15): 1685–92. doi:10.1001/jama.2009.1498. PMID   19843904. S2CID   25598632.
  57. ↑ Carroll PR, Whitson JM, Cooperberg MR (February 2011). "Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?". Journal of Clinical Oncology. 29 (4): 345–7. doi: 10.1200/JCO.2010.32.5308 . PMID   21189396. S2CID   20098979.
  58. ↑ Collins MM, Barry MJ (December 1996). "Controversies in prostate cancer screening. Analogies to the early lung cancer screening debate". JAMA. 276 (24): 1976–9. doi:10.1001/jama.276.24.1976. PMID   8971068.
  59. 1 2 3 4 5 Anthony Horan (August 2009). The Big Scare: The Business of Prostate Cancer. STERLINGHOUSE. ISBN   978-1-58501-119-3 . Retrieved 18 August 2013.
  60. ↑ "Prostate cancer screening: Should you get a PSA test?" MayoClinic.com, updated March 6, 2010
  61. ↑ Haythorn MR, Ablin RJ (August 2011). "Prostate-specific antigen testing across the spectrum of prostate cancer". Biomarkers in Medicine . 5 (4): 515–26. doi:10.2217/bmm.11.53. PMID   21861672.
  62. 1 2 Chad-Friedman E, Coleman S, Traeger LN, Pirl WF, Goldman R, Atlas SJ, et al. (2017-10-15). "Psychological distress associated with cancer screening: A systematic review". Cancer. 123 (20): 3882–3894. doi:10.1002/cncr.30904. ISSN   0008-543X.
  63. ↑ Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. (March 2009). "Screening and prostate-cancer mortality in a randomized European study". The New England Journal of Medicine. 360 (13): 1320–8. doi:10.1056/NEJMoa0810084. hdl: 2027.42/137255 . PMID   19297566. S2CID   9602977.
  64. ↑ van Leeuwen PJ, Connolly D, Gavin A, Roobol MJ, Black A, Bangma CH, et al. (January 2010). "Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit". European Journal of Cancer. 46 (2): 377–83. doi:10.1016/j.ejca.2009.09.008. PMID   19804966. S2CID   207211780. Archived from the original on 2015-09-01. Retrieved 2019-02-02.
  65. ↑ ProtecT (July 25, 2007). "ProtecT Study (Prostate testing for cancer and Treatment)". University of Bristol Dept. of Social Medicine. Archived from the original on 2007-10-28. Retrieved 2007-11-19.
    ISRCTN (March 6, 2006). "The CAP (Comparison Arm for ProtecT) study". isrctn.org. doi: 10.1186/ISRCTN92187251 .
    ISRCTN (November 19, 2007). "The ProtecT trial". isrctn.org. doi: 10.1186/ISRCTN20141297 .
  66. ↑ "Outline of the ProtecT study and its data and samples". Bristol Medical School: Population Health Sciences.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.